Avid Press Releases and Molecular Imaging in the Media

View all...

At Avid, a wholly-owned subsidiary of Eli Lilly and Company (NYSE:LLY), our mission is to develop new molecular imaging agents capable of changing the medical management of significant chronic human diseases by identifying the first stages of pathological change, potentially assisting in earlier diagnosis, better management and the development of new therapies.

We’re hiring! Click here for our current list of vacancies